Developing future treatments
Scientific and technological advances have led to a growing treatment pipeline for the diseases that cause dementia, with the first new treatment which slows cognitive decline in people with early-stage Alzheimer’s already available in the US and soon to be reviewed for use in the UK and Europe.
The potential for this pipeline to deliver life-changing treatments to people living with dementia in the UK in the very near future depends on a number of factors including the speed and scale of clinical trials and where these are located.
It will also be important that the healthcare system is ready to deliver new treatments to people who can benefit from them as quickly as possible and wherever they live in the UK.
The Future of Clinical Trials. Alzheimer’s Research UK Report 2021.
Cummings et al., (2022) Alzheimer’s disease drug development pipeline.
Are we ready to deliver disease modifying treatments, ARUK report 2021.